Advanced Search

The American Journal of Psychiatry, VOL. 161, No. 7

Letter to the Editor | July 01, 2004

Drs. Murphy and Schatzberg Reply

GREER M. MURPHY, M.D., Ph.D.; ALAN F. SCHATZBERG, M.D.

Am J Psychiatry 2004;161:1309-1309. 10.1176/appi.ajp.161.7.1309

Article

References

text A A A

To the Editor: We appreciate Dr. Härtter’s comments on our finding that the CYP2D6 genotype had no effect on the efficacy or tolerability of paroxetine or mirtazapine. He asserts that a difference would not be expected between CYP2D6 genotype groups at a 40 mg/day dose of paroxetine but that an effect would be apparent had we used a lower dose. However, all paroxetine-treated patients received 20 mg/day of this medication for 2 full weeks. There were no significant differences between the CYP2D6 genotype groups in patients receiving 20 mg/day of paroxetine.

Dr. Härtter questions the role of CYP2D6 in the metabolism of mirtazapine. Stormer and colleagues (1) reported a significant role for CYP2D6 in the metabolism of mirtazapine. Furthermore, Kirchheiner et al. (2), who presented dosing guidelines for many antidepressants based on CYP2D6 genotypes, recommended additional research on the impact of CYP2D6 polymorphisms on mirtazapine.

Dr. Härtter considers it "wrong" to study the effects of CYP2D6 genetic variation on paroxetine treatment outcomes. However, as he notes, there is ample support for the role of CYP2D6 in the metabolism of this medication. In addition, Kirchheiner and colleagues (2) recommended major reductions in paroxetine dosing in CYP2D6 poor metabolizers. We found no support for these recommendations.

Dr. Härtter states there is growing evidence that consideration of pharmacokinetics can improve psychotropic efficacy and safety. Actually, the relevance of cytochrome enzymes to clinical psychiatry has been debated for a number of years without resolution. One reason for this continuing controversy is the paucity of prospective pharmacogenetic outcome data from well-designed clinical trials. We believe that our study was the first in psychiatry to actually test prospectively the role of the CYP2D6 genotype on clinical outcomes by using two widely prescribed medications and a statistically meaningful group size.

Finally, we agree with Dr. Härtter that pharmacokinetic considerations can be important in certain clinical settings, but our data indicate that pharmacokinetic variation due to the CYP2D6 genotype should not be a major concern for clinicians during monotherapy with paroxetine or mirtazapine. It is possible that complex interactions may occur between concurrently administered CYP2D6 substrates and inhibitors and that these interactions may be affected by the CYP2D6 genotype. However, we found no such interactions between the CYP2D6 genotype and concurrent medications that affected paroxetine or mirtazapine outcomes. We noted that our results may not apply to other medications, and we hope there will be additional prospective pharmacogenetic trials with other antidepressants.

References

Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28:1168–1175[PubMed]

Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173–192[PubMed][CrossRef]

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Drs. Murphy and Schatzberg Reply' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'Drs. Murphy and Schatzberg Reply'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

GREER M. MURPHY, Jr., ALAN F. SCHATZBERG; Drs. Murphy and Schatzberg Reply. American Journal of Psychiatry. 2004 Jul;161(7):1309-1309.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints